News articles for Ligand Pharmaceuticals Incorporated:
Thursday, February 9, 2012
Tuesday, February 7, 2012
Wednesday, February 1, 2012
Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that
results from the Phase II study of its Captisol-enabled, propylene
glycol-free (PG-free) Melphalan program were featured this evening in a
...
read moreWednesday, January 4, 2012
Wednesday, December 21, 2011
Wednesday, December 7, 2011
Tuesday, November 8, 2011
Monday, November 7, 2011
Wednesday, November 2, 2011
Wednesday, October 19, 2011